A citation-based method for searching scientific literature

Ikuro Matsuba, Takehiro Kawata, Kotaro Iemitsu, Taro Asakura, Hikaru Amemiya, Masashi Ishikawa, Syogo Ito, Mizuki Kaneshiro, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Masahiko Takai, Tetsuo Takuma, Masahiro Takihata, Hiroshi Takeda, Keiji Tanaka, Yoko Matsuzawa, Hideo Machimura, Fuyuki Minagawa, Nobuaki Minami, Atsuko Mokubo, Masaaki Miyakawa, Yasuo Terauchi, Yasushi Tanaka. J Diabetes Investig 2020
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
92
100

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Terrance D Barrett, Michele Weidner-Wells, Hsiaowei Deng, David R Matthews,[...]. Lancet Diabetes Endocrinol 2018
247
50

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Erik J van Bommel, Hiddo J L Heerspink, Daniël H van Raalte, Jaap A Joles. J Am Soc Nephrol 2017
225
50

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
187
50

A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen.
T Tanaka, T Okamura, K Miura, T Kadowaki, H Ueshima, H Nakagawa, T Hashimoto. J Hum Hypertens 2002
387
50

The Landscape of Diabetic Kidney Disease in the United States.
O Kenrik Duru, Tim Middleton, Mona K Tewari, Keith Norris. Curr Diab Rep 2018
15
50

One-year eGFR decline rate is a good predictor of prognosis of renal failure in patients with type 2 diabetes.
Jun Nojima, Shu Meguro, Naoto Ohkawa, Michiaki Furukoshi, Toshihide Kawai, Hiroshi Itoh. Proc Jpn Acad Ser B Phys Biol Sci 2017
10
50


Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, Megumi Oshima, Rajiv Agarwal, George Bakris, Harpreet S Bajaj, Scott Bull, Christopher P Cannon, David M Charytan,[...]. J Am Soc Nephrol 2020
39
50

Correlation of body muscle/fat ratio with insulin sensitivity using hyperinsulinemic-euglycemic clamp in treatment-naïve type 2 diabetes mellitus.
Noboru Kurinami, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Fumio Miyamoto, Keizo Kajiwara, Tomio Jinnouchi, Hideaki Jinnouchi. Diabetes Res Clin Pract 2016
16
50

Revised equations for estimated GFR from serum creatinine in Japan.
Seiichi Matsuo, Enyu Imai, Masaru Horio, Yoshinari Yasuda, Kimio Tomita, Kosaku Nitta, Kunihiro Yamagata, Yasuhiko Tomino, Hitoshi Yokoyama, Akira Hishida. Am J Kidney Dis 2009
50

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
Christoph Wanner, Hiddo J L Heerspink, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Stefan Hantel, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten,[...]. J Am Soc Nephrol 2018
68
50

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara,[...]. J Atheroscler Thromb 2018
32
50

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
50

New pharmacological strategies for protecting kidney function in type 2 diabetes.
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. Lancet Diabetes Endocrinol 2019
36
50

Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Motoko Tanaka, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto,[...]. J Clin Med Res 2018
9
50

The tubular hypothesis of nephron filtration and diabetic kidney disease.
Volker Vallon, Scott C Thomson. Nat Rev Nephrol 2020
61
50

Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
Seigo Sugiyama, Hideaki Jinnouchi, Akira Yoshida, Kunio Hieshima, Noboru Kurinami, Katsunori Jinnouchi, Motoko Tanaka, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara,[...]. J Clin Med Res 2019
12
50


Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
252
50





Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
353
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50



Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Clare Arnott, Qiang Li, Amy Kang, Brendon L Neuen, Severine Bompoint, Carolyn S P Lam, Anthony Rodgers, Kenneth W Mahaffey, Christopher P Cannon, Vlado Perkovic,[...]. J Am Heart Assoc 2020
79
50


Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Takeshi Kadokura, Noriko Akiyama, Atsunori Kashiwagi, Atsushi Utsuno, Kenichi Kazuta, Satoshi Yoshida, Itsuro Nagase, Ronald Smulders, Shigeru Kageyama. Diabetes Res Clin Pract 2014
28
50



Diabetes, prediabetes and uricaemia.
J B Herman, J H Medalie, U Goldbourt. Diabetologia 1976
72
50

Close correlation between visceral fat accumulation and uric acid metabolism in healthy men.
S Takahashi, T Yamamoto, Z Tsutsumi, Y Moriwaki, J Yamakita, K Higashino. Metabolism 1997
91
50

Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Masashi Tanaka, Hajime Yamakage, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Akira Shimatsu, Noriko Satoh-Asahara. Intern Med 2020
4
50


Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
J-F Yale, G Bakris, B Cariou, D Yue, E David-Neto, L Xi, K Figueroa, E Wajs, K Usiskin, G Meininger. Diabetes Obes Metab 2013
360
50

Japanese Clinical Practice Guideline for Diabetes 2019.
Eiichi Araki, Atsushi Goto, Tatsuya Kondo, Mitsuhiko Noda, Hiroshi Noto, Hideki Origasa, Haruhiko Osawa, Akihiko Taguchi, Yukio Tanizawa, Kazuyuki Tobe,[...]. Diabetol Int 2020
43
50


Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study.
Hyon K Choi, Karen Atkinson, Elizabeth W Karlson, Gary Curhan. Arch Intern Med 2005
347
50

Assessment of the relationship between serum uric acid and glucose levels in healthy, prediabetic and diabetic individuals.
Tangigul Haque, Sadaqur Rahman, Shiful Islam, Noyan Hossain Molla, Nurshad Ali. Diabetol Metab Syndr 2019
20
50

Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.
Nathan R Hill, Samuel T Fatoba, Jason L Oke, Jennifer A Hirst, Christopher A O'Callaghan, Daniel S Lasserson, F D Richard Hobbs. PLoS One 2016
50



An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013).
Ikuto Masakane, Shigeru Nakai, Satoshi Ogata, Naoki Kimata, Norio Hanafusa, Takayuki Hamano, Kenji Wakai, Atsushi Wada, Kosaku Nitta. Ther Apher Dial 2015
168
50

Time to target uric acid to retard CKD progression.
Takanori Kumagai, Tatsuru Ota, Yoshifuru Tamura, Wen Xiu Chang, Shigeru Shibata, Shunya Uchida. Clin Exp Nephrol 2017
38
50

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.
Yukihiro Chino, Yoshishige Samukawa, Soichi Sakai, Yasuhiro Nakai, Jun-ichi Yamaguchi, Takeo Nakanishi, Ikumi Tamai. Biopharm Drug Dispos 2014
162
50

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data.
Morgan E Grams, Yingying Sang, Shoshana H Ballew, Kunihiro Matsushita, Brad C Astor, Juan Jesus Carrero, Alex R Chang, Lesley A Inker, Timothy Kenealy, Csaba P Kovesdy,[...]. J Am Soc Nephrol 2019
42
50

SGLT2 Inhibitors and the Diabetic Kidney.
Paola Fioretto, Alberto Zambon, Marco Rossato, Luca Busetto, Roberto Vettor. Diabetes Care 2016
152
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.